Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients.
Mortality
SPD-1
SPD-L1
Severe pneumonia
Traumatic brain Injury
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 Oct 2024
11 Oct 2024
Historique:
received:
20
05
2024
accepted:
26
09
2024
medline:
12
10
2024
pubmed:
12
10
2024
entrez:
11
10
2024
Statut:
epublish
Résumé
Patients with traumatic brain injury (TBI) frequently exhibit concomitant immunosuppression. In this study, we evaluated the predictive values of soluble programmed death-1 (sPD-1) and soluble programmed death ligand-1 (sPD-L1) in patients with severe TBI. Peripheral blood sPD-1 and sPD-L1 levels were measured within 48 h of patient admission. A total of 20 healthy volunteers and 82 patients were enrolled in this study. The levels of sPD-1 and sPD-L1 were upregulated in patients with severe TBI (P < 0.001). They were significantly increased in the post-TBI severe pneumonia group and among non-survivors (P < 0.001). The area under the curves (AUCs) for sPD-1 and sPD-L1 levels to predict severe pneumonia were 0.714 and 0.696, respectively, and the AUCs to predict mortality were 0.758 and 0.735. The levels of sPD-1 and sPD-L1 are correlated with the GCS scores at admission, APACHE II scores, length of MV, and time elapsed to mortality. The levels of sPD-1 and sPD-L1 emerged as independent predictive factors for severe pneumonia and mortality. This study demonstrates that upregulation of sPD-1 and sPD-L1 in severe TBI patients is significantly associated with severe pneumonia and mortality, suggesting their potential as predictive biomarkers for these outcomes.
Identifiants
pubmed: 39394380
doi: 10.1038/s41598-024-74520-3
pii: 10.1038/s41598-024-74520-3
doi:
Substances chimiques
B7-H1 Antigen
0
Programmed Cell Death 1 Receptor
0
Biomarkers
0
CD274 protein, human
0
PDCD1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23791Subventions
Organisme : the Foundation for the School Health Association of Shandong
ID : SDWS2022186
Organisme : Dongying Natural Science Foundation
ID : 2023ZR036
Informations de copyright
© 2024. The Author(s).
Références
Guan, B., Anderson, D. B., Chen, L., Feng, S. & Zhou, H. Global, regional and national burden of traumatic brain injury and spinal cord injury, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. BMJ Open. 13, e075049 (2023).
doi: 10.1136/bmjopen-2023-075049
pubmed: 37802626
pmcid: 10565269
Lassarén, P. et al. Systemic inflammation alters the neuroinflammatory response: a prospective clinical trial in traumatic brain injury. J. Neuroinflammation. 18, 221 (2021).
doi: 10.1186/s12974-021-02264-2
pubmed: 34563211
pmcid: 8464153
Sharma, R. et al. Infections after a traumatic brain injury: the complex interplay between the immune and neurological systems. Brain Behav. Immun. 79, 63–74 (2019).
doi: 10.1016/j.bbi.2019.04.034
pubmed: 31029794
Bao, W., Lin, Y. & Chen, Z. The Peripheral Immune System and Traumatic Brain Injury: insight into the role of T-helper cells. Int. J. Med. Sci. 18, 3644–3651 (2021).
doi: 10.7150/ijms.46834
pubmed: 34790036
pmcid: 8579286
Chen, Y. et al. The implication of targeting PD-1:PD-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways. Front. Immunol. 14, 1323797 (2023).
doi: 10.3389/fimmu.2023.1323797
pubmed: 38193090
pmcid: 10773890
Peng, Q. et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat. Commun.11, 4835 (2020).
doi: 10.1038/s41467-020-18570-x
pubmed: 32973173
pmcid: 7518441
Gianchecchi, E., Delfino, D. V. & Fierabracci, A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun. Rev. 12, 1091–1100 (2013).
doi: 10.1016/j.autrev.2013.05.003
pubmed: 23792703
Du, Y. et al. Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity. Scand. J. Immunol. 92, e12884 (2020).
doi: 10.1111/sji.12884
pubmed: 32243638
Niu, M., Liu, Y., Yi, M., Jiao, D. & Wu, K. Biological characteristics and clinical significance of Soluble PD-1/PD-L1 and exosomal PD-L1 in Cancer. Front. Immunol. 13, 827921 (2022).
doi: 10.3389/fimmu.2022.827921
pubmed: 35386715
pmcid: 8977417
Sari, M. I. & Ilyas, S. The expression levels and concentrations of PD-1 and PD-L1 proteins in septic patients: a systematic review. Diagnostics (Basel) 12, (2022).
Mehta, R. & Chinthapalli, K. Glasgow coma scale explained. Bmj. 365, l1296 (2019).
doi: 10.1136/bmj.l1296
pubmed: 31048343
Carney, N. et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery 80, 6–15 (2017).
doi: 10.1227/NEU.0000000000001432
pubmed: 27654000
Mandell, L. A. et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44 (Suppl 2), S27–72 (2007).
doi: 10.1086/511159
pubmed: 17278083
Vermeij, J. D. et al. Traumatic brain injury in rats induces lung injury and systemic immune suppression. J. Neurotrauma. 30, 2073–2079 (2013).
doi: 10.1089/neu.2013.3060
pubmed: 23937270
Geng, X. et al. Construction and validation of a predictive model of pneumonia for ICU patients with traumatic brain injury (TBI). Neurosurg. Rev. 46, 308 (2023).
doi: 10.1007/s10143-023-02208-9
pubmed: 37985473
Liu, M. et al. Serum sPD-L1, upregulated in Sepsis, May reflect Disease Severity and clinical outcomes in septic patients. Scand. J. Immunol. 85, 66–72 (2017).
doi: 10.1111/sji.12509
pubmed: 27864994
Sun, S. et al. Serum-soluble PD-L1 may be a potential diagnostic biomarker in sepsis. Scand. J. Immunol. 94, e13049 (2021).
doi: 10.1111/sji.13049
pubmed: 33934376
Chen, R. & Zhou, L. PD-1 signaling pathway in sepsis: does it have a future? Clin. Immunol. 229, 108742 (2021).
doi: 10.1016/j.clim.2021.108742
pubmed: 33905818
Zhao, Y., Jia, Y., Li, C., Shao, R. & Fang, Y. Predictive value of Soluble programmed Death-1 for severe Sepsis and septic shock during the First Week in an Intensive Care Unit. Shock. 51, 289–297 (2019).
doi: 10.1097/SHK.0000000000001171
pubmed: 29702526
Wan, B. et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177, 8844–8850 (2006).
doi: 10.4049/jimmunol.177.12.8844
pubmed: 17142787
Wu, H. et al. Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia. Immunol. Invest. 38, 408–421 (2009).
doi: 10.1080/08820130902912332
pubmed: 19811417
Monaghan, S. F. et al. Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS). J. Transl Med. 14, 312, (2016).
Wang, R., Hua, Y., He, M. & Xu, J. Prognostic value of serum procalcitonin based model in moderate to severe traumatic brain Injury patients. J. Inflamm. Res. 15, 4981–4993 (2022).
doi: 10.2147/JIR.S358621
pubmed: 36065318
pmcid: 9440674
Vincent, J. L. & Moreno, R. Clinical review: scoring systems in the critically ill. Crit. Care. 14, 207 (2010).
doi: 10.1186/cc8204
pubmed: 20392287
pmcid: 2887099
Raj, R. et al. Predicting six-month mortality of patients with traumatic brain injury: usefulness of common intensive care severity scores. Crit. Care. 18, R60 (2014).
doi: 10.1186/cc13814
pubmed: 24708781
pmcid: 4056363
Magatti, M. et al. Systemic immune response in young and elderly patients after traumatic brain injury. Immun. Ageing 20, 41, (2023).